Sathish Krishnan, Vijaya Sivalingam Ramalingam, Chandrika Patel, Jennifer Heisick
{"title":"原发性肺平滑肌肉瘤:一个90岁女性放疗和帕唑帕尼延长生存的案例。","authors":"Sathish Krishnan, Vijaya Sivalingam Ramalingam, Chandrika Patel, Jennifer Heisick","doi":"10.1002/rcr2.70301","DOIUrl":null,"url":null,"abstract":"<p><p>Primary pulmonary leiomyosarcoma is an exceedingly rare malignancy, comprising less than 0.5% of all lung cancers. Due to its rarity, no standardised treatment guidelines exist. Prognosis is especially poor in cases which are deemed unresectable. We describe the case of a 90-year-old woman who presented with progressive dyspnea and cough over 1 month. Chest computed tomography revealed a large right hilar mass extending into the right upper and middle lobes, abutting the mediastinum and pericardium. Histopathological analysis confirmed primary pulmonary leiomyosarcoma. Given her advanced age and comorbidities, she was not a candidate for surgical intervention. Molecular profiling demonstrated PDL1 expression < 1% and no targetable mutations, ruling out the option of immunotherapy. She was managed with palliative radiotherapy followed by pazopanib therapy. Serial imaging demonstrated disease control, with an extended survival of approximately 5 years. Despite a median reported survival of 14 months, our patient achieved prolonged survival, highlighting the importance of an individualised therapeutic approach for elderly patients with rare malignancies.</p>","PeriodicalId":45846,"journal":{"name":"Respirology Case Reports","volume":"13 7","pages":"e70301"},"PeriodicalIF":0.8000,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12303610/pdf/","citationCount":"0","resultStr":"{\"title\":\"Primary Pulmonary Leiomyosarcoma: A Case of Prolonged Survival With Radiotherapy and Pazopanib in a 90-Year-Old Female.\",\"authors\":\"Sathish Krishnan, Vijaya Sivalingam Ramalingam, Chandrika Patel, Jennifer Heisick\",\"doi\":\"10.1002/rcr2.70301\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Primary pulmonary leiomyosarcoma is an exceedingly rare malignancy, comprising less than 0.5% of all lung cancers. Due to its rarity, no standardised treatment guidelines exist. Prognosis is especially poor in cases which are deemed unresectable. We describe the case of a 90-year-old woman who presented with progressive dyspnea and cough over 1 month. Chest computed tomography revealed a large right hilar mass extending into the right upper and middle lobes, abutting the mediastinum and pericardium. Histopathological analysis confirmed primary pulmonary leiomyosarcoma. Given her advanced age and comorbidities, she was not a candidate for surgical intervention. Molecular profiling demonstrated PDL1 expression < 1% and no targetable mutations, ruling out the option of immunotherapy. She was managed with palliative radiotherapy followed by pazopanib therapy. Serial imaging demonstrated disease control, with an extended survival of approximately 5 years. Despite a median reported survival of 14 months, our patient achieved prolonged survival, highlighting the importance of an individualised therapeutic approach for elderly patients with rare malignancies.</p>\",\"PeriodicalId\":45846,\"journal\":{\"name\":\"Respirology Case Reports\",\"volume\":\"13 7\",\"pages\":\"e70301\"},\"PeriodicalIF\":0.8000,\"publicationDate\":\"2025-07-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12303610/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Respirology Case Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1002/rcr2.70301\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/7/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q4\",\"JCRName\":\"RESPIRATORY SYSTEM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Respirology Case Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/rcr2.70301","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
Primary Pulmonary Leiomyosarcoma: A Case of Prolonged Survival With Radiotherapy and Pazopanib in a 90-Year-Old Female.
Primary pulmonary leiomyosarcoma is an exceedingly rare malignancy, comprising less than 0.5% of all lung cancers. Due to its rarity, no standardised treatment guidelines exist. Prognosis is especially poor in cases which are deemed unresectable. We describe the case of a 90-year-old woman who presented with progressive dyspnea and cough over 1 month. Chest computed tomography revealed a large right hilar mass extending into the right upper and middle lobes, abutting the mediastinum and pericardium. Histopathological analysis confirmed primary pulmonary leiomyosarcoma. Given her advanced age and comorbidities, she was not a candidate for surgical intervention. Molecular profiling demonstrated PDL1 expression < 1% and no targetable mutations, ruling out the option of immunotherapy. She was managed with palliative radiotherapy followed by pazopanib therapy. Serial imaging demonstrated disease control, with an extended survival of approximately 5 years. Despite a median reported survival of 14 months, our patient achieved prolonged survival, highlighting the importance of an individualised therapeutic approach for elderly patients with rare malignancies.
期刊介绍:
Respirology Case Reports is an open-access online journal dedicated to the publication of original clinical case reports, case series, clinical images and clinical videos in all fields of respiratory medicine. The Journal encourages the international exchange between clinicians and researchers of experiences in diagnosing and treating uncommon diseases or diseases with unusual presentations. All manuscripts are peer-reviewed through a streamlined process that aims at providing a rapid turnaround time from submission to publication.